BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 11598842)

  • 21. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine.
    Brown DR; Fife KH; Wheeler CM; Koutsky LA; Lupinacci LM; Railkar R; Suhr G; Barr E; Dicello A; Li W; Smith JF; Tadesse A; Jansen KU
    Vaccine; 2004 Jul; 22(21-22):2936-42. PubMed ID: 15246630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
    Stanley M; Lowy DR; Frazer I
    Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.
    Kirnbauer R; Chandrachud LM; O'Neil BW; Wagner ER; Grindlay GJ; Armstrong A; McGarvie GM; Schiller JT; Lowy DR; Campo MS
    Virology; 1996 May; 219(1):37-44. PubMed ID: 8623552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women.
    Fife KH; Wheeler CM; Koutsky LA; Barr E; Brown DR; Schiff MA; Kiviat NB; Jansen KU; Barber H; Smith JF; Tadesse A; Giacoletti K; Smith PR; Suhr G; Johnson DA
    Vaccine; 2004 Jul; 22(21-22):2943-52. PubMed ID: 15246631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine.
    Emeny RT; Wheeler CM; Jansen KU; Hunt WC; Fu TM; Smith JF; MacMullen S; Esser MT; Paliard X
    J Virol; 2002 Aug; 76(15):7832-42. PubMed ID: 12097595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
    Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
    Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
    Park JS; Oh YK; Kang MJ; Kim CK
    J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Papillomavirus-like particles for serology and vaccine development.
    Kirnbauer R
    Intervirology; 1996; 39(1-2):54-61. PubMed ID: 8957670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera.
    Rose RC; Reichman RC; Bonnez W
    J Gen Virol; 1994 Aug; 75 ( Pt 8)():2075-9. PubMed ID: 8046412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review.
    Ault KA
    Obstet Gynecol Surv; 2006 Jun; 61(6 Suppl 1):S26-31. PubMed ID: 16729901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration.
    Bryan JT; Jansen KU; Lowe RS; Fife KH; McClowry T; Glass D; Brown DR
    J Med Virol; 1997 Nov; 53(3):185-8. PubMed ID: 9365880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Vaccination against human papillomavirus and against the cellular proliferation that it induces: facts and expectations].
    Giannouli C; Burny A; Hallez S
    J Gynecol Obstet Biol Reprod (Paris); 2000 May; 29(3):258-60. PubMed ID: 10804365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast.
    Lowe RS; Brown DR; Bryan JT; Cook JC; George HA; Hofmann KJ; Hurni WM; Joyce JG; Lehman ED; Markus HZ; Neeper MP; Schultz LD; Shaw AR; Jansen KU
    J Infect Dis; 1997 Nov; 176(5):1141-5. PubMed ID: 9359711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.
    Nardelli-Haefliger D; Roden RB; Benyacoub J; Sahli R; Kraehenbuhl JP; Schiller JT; Lachat P; Potts A; De Grandi P
    Infect Immun; 1997 Aug; 65(8):3328-36. PubMed ID: 9234794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells.
    Mossadegh N; Gissmann L; Müller M; Zentgraf H; Alonso A; Tomakidi P
    Virology; 2004 Aug; 326(1):57-66. PubMed ID: 15262495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cervical cancer prevention: the impact of HPV vaccination].
    Monsonégo J
    Gynecol Obstet Fertil; 2006 Mar; 34(3):189-201. PubMed ID: 16529969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strategies for the prevention of cervical cancer by human papillomavirus vaccination.
    Williamson AL; Passmore JA; Rybicki EP
    Best Pract Res Clin Obstet Gynaecol; 2005 Aug; 19(4):531-44. PubMed ID: 16150392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunogenicity study of HPV 6b virus-like particles].
    Liu Y; Liu X; Frazer IH
    Zhonghua Yi Xue Za Zhi; 2002 May; 82(9):587-9. PubMed ID: 12133476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women.
    Viscidi RP; Ahdieh-Grant L; Clayman B; Fox K; Massad LS; Cu-Uvin S; Shah KV; Anastos KM; Squires KE; Duerr A; Jamieson DJ; Burk RD; Klein RS; Minkoff H; Palefsky J; Strickler H; Schuman P; Piessens E; Miotti P
    J Infect Dis; 2003 Jan; 187(2):194-205. PubMed ID: 12552444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain.
    Ludmerer SW; McClements WL; Wang XM; Ling JC; Jansen KU; Christensen ND
    Virology; 2000 Jan; 266(2):237-45. PubMed ID: 10639310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.